Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases

Journal of Medicinal Chemistry
Scott J HeckerMichael N Dudley

Abstract

The increasing dissemination of carbapenemases in Gram-negative bacteria has threatened the clinical usefulness of the β-lactam class of antimicrobials. A program was initiated to discover a new series of serine β-lactamase inhibitors containing a boronic acid pharmacophore, with the goal of finding a potent inhibitor of serine carbapenemase enzymes that are currently compromising the utility of the carbapenem class of antibacterials. Potential lead structures were screened in silico by modeling into the active sites of key serine β-lactamases. Promising candidate molecules were synthesized and evaluated in biochemical and whole-cell assays. Inhibitors were identified with potent inhibition of serine carbapenemases, particularly the Klebsiella pneumoniae carbapenemase (KPC), with no inhibition of mammalian serine proteases. Studies in vitro and in vivo show that RPX7009 (9f) is a broad-spectrum inhibitor, notably restoring the activity of carbapenems against KPC-producing strains. Combined with a carbapenem, 9f is a promising product for the treatment of multidrug resistant Gram-negative bacteria.

References

Jan 1, 1978·The Biochemical Journal·P A Kiener, S G Waley
Sep 1, 1982·The Biochemical Journal·S G Waley
Aug 1, 1996·Nature Structural Biology·N C StrynadkaJ B Jones
Jan 16, 2003·Journal of the American Chemical Society·Federica MorandiFabio Prati
Jul 16, 2003·Biochemistry·Xiaojun WangBrian K Shoichet
Sep 1, 1994·Acta Crystallographica. Section D, Biological Crystallography·UNKNOWN Collaborative Computational Project, Number 4
May 1, 1997·Acta Crystallographica. Section D, Biological Crystallography·G N MurshudovE J Dodson
Dec 14, 2006·Acta Crystallographica. Section D, Biological Crystallography·Airlie J McCoy
Jan 9, 2010·Acta Crystallographica. Section D, Biological Crystallography·Vincent B ChenDavid C Richardson
Feb 4, 2010·Acta Crystallographica. Section D, Biological Crystallography·Wolfgang Kabsch
Apr 13, 2010·Acta Crystallographica. Section D, Biological Crystallography·P EmsleyK Cowtan
Apr 7, 2012·Trends in Molecular Medicine·Patrice NordmannLaurent Poirel
Apr 24, 2012·Chemical Reviews·Reem SmoumMorris Srebnik
Jun 12, 2013·Expert Review of Anti-infective Therapy·Richard R Watkins, Robert A Bonomo

❮ Previous
Next ❯

Citations

Jan 16, 2016·Journal of Medicinal Chemistry·Sabin Llona-MinguezThomas Helleday
Nov 27, 2015·Expert Opinion on Pharmacotherapy·Shang-Yi LinPo-Ren Hsueh
Mar 24, 2016·International Journal of Antimicrobial Agents·Ling-Shan SyuePo-Ren Hsueh
Nov 14, 2014·Chemical Biology & Drug Design·Erin E GillRobert E W Hancock
May 22, 2016·Infectious Disease Clinics of North America·Krisztina M Papp-Wallace, Robert A Bonomo
Jun 16, 2016·Future Medicinal Chemistry·Fernando CoronaJosé L Martínez
Oct 28, 2016·Journal of Computer-aided Molecular Design·Jacopo SgrignaniGiovanni Grazioso
Dec 15, 2016·Journal of Medicinal Chemistry·Christoph NitscheChristian D Klein
Dec 21, 2016·Protein Science : a Publication of the Protein Society·Josephine P WernerRachel A Powers
Mar 18, 2017·Drugs·Darren Wong, David van Duin
May 23, 2017·Natural Product Reports·P Klahn, M Brönstrup
Mar 24, 2016·Angewandte Chemie·Mathieu F ChellatRainer Riedl
Jun 9, 2017·Journal of Medicinal Chemistry·Domenico SchillaciStella Cascioferro
Oct 18, 2016·MedChemComm·Jed F Fisher, Shahriar Mobashery
Sep 20, 2016·MedChemComm·Jesse A JonesKirk E Hevener
Jul 30, 2017·Nature Chemistry·Diego B Diaz, Andrei K Yudin
Feb 11, 2018·Pharmacotherapy·Sarah Christina Jane Jorgensen, Michael Joseph Rybak
Feb 9, 2016·Chemical Society Reviews·Patricia AndrésCarlos Cativiela
Nov 1, 2017·Antimicrobial Agents and Chemotherapy·Meredith A HackelDaniel F Sahm
Oct 19, 2017·Antimicrobial Agents and Chemotherapy·Debora Rubio-AparicioOlga Lomovskaya
Oct 19, 2017·Antimicrobial Agents and Chemotherapy·William J WeissDavid C Griffith
Jan 10, 2018·Antimicrobial Agents and Chemotherapy·Christopher M RubinoDavid C Griffith
Feb 16, 2018·Clinical Microbiology Reviews·Jesús Rodríguez-BañoAlvaro Pascual
May 31, 2018·Antimicrobial Agents and Chemotherapy·Orville A PembertonYu Chen
Jul 24, 2018·Expert Opinion on Emerging Drugs·Marco ManteroMarta Di Pasquale
Aug 15, 2018·Expert Opinion on Drug Metabolism & Toxicology·Rodrigo M BurgosLarry H Danziger
Aug 30, 2017·Antimicrobial Agents and Chemotherapy·Olga LomovskayaMichael N Dudley
Jan 6, 2016·Antimicrobial Agents and Chemotherapy·Nhu Q NguyenFocco van den Akker
Jan 25, 2017·Antimicrobial Agents and Chemotherapy·Samuel T CahillJürgen Brem
Jul 10, 2018·The Journal of Antimicrobial Chemotherapy·Menglan ZhouYingchun Xu
Sep 10, 2015·Antimicrobial Agents and Chemotherapy·Eric WenzlerKeith A Rodvold
Nov 18, 2018·Expert Review of Clinical Pharmacology·Daniele Roberto GiacobbeClaudio Viscoli
Nov 7, 2018·Antimicrobial Agents and Chemotherapy·David C GriffithMichael N Dudley
Feb 23, 2019·Journal of the Pediatric Infectious Diseases Society·Pranita D Tamma, Alice J Hsu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Bacterial Protein Structures

Bacterial protein structures can expedite the development of novel antibiotics. Here is the latest research on bacterial proteins and the resolution of their structures.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Bacterial Protein Structures (ASM)

Bacterial protein structures can expedite the development of novel antibiotics. Here is the latest research on bacterial proteins and the resolution of their structures.